This, taken in context with established risk factors for HCC, i.e., cirrhosis, hepatitis B, and a past history of HCC, may allow a similar probability scale for HCC diagnosis to be developed for PSMA PET as for other contrast-enhanced imaging. The gene discussed is FOLH1; the disease is hepatocellular carcinoma.